| A comparative review of generic quality-of-life instruments SJ Coons, S Rao, DL Keininger, RD Hays Pharmacoeconomics 17 (1), 13-35, 2000 | 1206 | 2000 |
| Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: A population‐based study SM Szabo, AR Levy, SR Rao, SE Kirbach, D Lacaille, M Cifaldi, ... Arthritis & Rheumatism 63 (11), 3294-3304, 2011 | 260 | 2011 |
| Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert … V Strand, SA Rao, AC Shillington, MA Cifaldi, M Mcguire, EM Ruderman Arthritis care & research 65 (8), 1299-1306, 2013 | 143 | 2013 |
| Cost of illness associated with metastatic breast cancer S Rao, J Kubisiak, D Gilden Breast cancer research and treatment 83 (1), 25-32, 2004 | 106 | 2004 |
| Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer D Waterhouse, J Lam, KA Betts, L Yin, S Gao, Y Yuan, J Hartman, S Rao, ... Lung Cancer 156, 41-49, 2021 | 100 | 2021 |
| Treatment-free survival: a novel outcome measure of the effects of immune checkpoint inhibition—a pooled analysis of patients with advanced melanoma MM Regan, L Werner, S Rao, K Gupte-Singh, FS Hodi, JM Kirkwood, ... Journal of Clinical Oncology 37 (35), 3350-3358, 2019 | 70 | 2019 |
| Estimating the occurrence of renal complications among persons with ankylosing spondylitis AR Levy, SM Szabo, SR Rao, M Cifaldi, WP Maksymowych Arthritis care & research 66 (3), 440-445, 2014 | 57 | 2014 |
| Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents X Gao, D Wendling, MF Botteman, JA Carter, S Rao, M Cifaldi Journal of Medical Economics, 1-10, 2012 | 56 | 2012 |
| Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma A Aly, C Johnson, S Yang, MF Botteman, S Rao, A Hussain Journal of medical economics 22 (7), 662-670, 2019 | 43 | 2019 |
| Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect … MB Atkins, A Tarhini, M Rael, K Gupte-Singh, E O’Brien, C Ritchings, ... Immunotherapy 11 (7), 617-629, 2019 | 33 | 2019 |
| Matching-Adjusted Indirect Comparison of Adalimumab vs. Etanercept and Infliximab for the Treatment of Psoriatic Arthritis KY Noam, R Sumati, HG Birnbaum, E Kantor, RS Wei, M Cifaldi Journal of Medical Economics, 1-37, 2013 | 31 | 2013 |
| Clinical and Economic Outcomes Associated with Treatment Sequences In Patients With BRAF-Mutant Advanced Melanoma A Tarhini, D McDermott, A Ambavane, K Gupte-Singh, V Aponte-Ribero, ... Immunotherapy 11 (4), 283-295, 2019 | 28 | 2019 |
| First-Line Immunotherapy Versus Targeted Therapy in Patients With BRAF-Mutant Advanced Melanoma: A Real-World Analysis AC Pavlick, R Zhao, CH Lee, C Ritchings, S Rao Future Oncology 17 (6), 689-699, 2021 | 27 | 2021 |
| Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost–effectiveness analysis A Tarhini, A Benedict, D McDermott, S Rao, A Ambavane, K Gupte-Singh, ... Immunotherapy 10 (14), 1241-1252, 2018 | 26 | 2018 |
| Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA A Tarhini, C Atzinger, K Gupte-Singh, C Johnson, C Macahilig, S Rao Journal of Comparative Effectiveness Research 8 (7), 461-473, 2019 | 24 | 2019 |
| A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆ AA Tarhini, K Toor, K Chan, DF McDermott, P Mohr, J Larkin, FS Hodi, ... ESMO open 6 (2), 100050, 2021 | 21 | 2021 |
| Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time … DF McDermott, R Shah, K Gupte-Singh, J Sabater, L Luo, M Botteman, ... Quality of Life Research 28, 109-119, 2019 | 20 | 2019 |
| Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy D Stenehjem, S Lubinga, KA Betts, W Tang, M Jenkins, Y Yuan, ... Future Oncology 17 (22), 2940-2949, 2021 | 18 | 2021 |
| Treatment sequences for advanced renal cell carcinoma: a health economic assessment B Deniz, A Ambavane, S Yang, A Altincatal, J Doan, S Rao, ... PLoS One 14 (8), e0215761, 2019 | 18 | 2019 |
| Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+ I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma … DF McDermott, BI Rini, RJ Motzer, NM Tannir, B Escudier, ... Annals of Oncology 29, viii309, 2018 | 18 | 2018 |
